ACV meeting statement, Meeting 19, 3 February 2021

Section A: Submissions for registration

The committee provided advice on one application to register a new vaccine.

Further details of the ACV discussion and advice associated with these pre-market items may be released within the Australian Public Assessment Report (AusPAR). Please note that there is a delay between when an application is considered by the ACV and the publication of the AusPAR. To browse all AusPARs see AusPAR search.

Section B: Safety

The committee provided further advice and endorsed the COVID-19 Vaccine Pharmacovigilance Plan, which had been amended following the ACV meeting 16 held 30 September 2020.

Further information

For further information on the ACV, please visit Advisory Committee on Vaccines or contact the ACV by email ACV@health.gov.au.